Trial Profile
A Phase II Study of Ipilimumab in Combination With Carboplatin and Paclitaxel in Patients With Unresectable Stage III or Stage IV Melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Carboplatin; Paclitaxel
- Indications Malignant melanoma
- Focus Adverse reactions
- 19 Dec 2019 Planned End Date changed from 1 Dec 2017 to 1 May 2026.
- 07 Jun 2019 Status changed from active, no longer recruiting to completed as per results presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology